The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review

被引：7

作者：

Ailani, Jessica ^{[1
]}

Nahas, Stephanie J. J. ^{[2
]}

Friedman, Deborah I. I. ^{[2
]}

Kunkel, Todd ^{[3
]}

机构：

[1] MedStar Georgetown Headache Ctr, Mclean, VA USA

[2] Thomas Jefferson Univ, Philadelphia, PA USA

[3] Coll Pharmaceut Inc, 100 Technol Ctr Dr,Suite 300, Stoughton, MA 02072 USA

来源：

PAIN AND THERAPY | 2023年 / 12卷 / 03期

关键词：

Nonsteroidal anti-inflammatory drugs; NSAIDs; Cyclooxygenase-2; inhibitor; COX-2; Migraine; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COX-2; INHIBITORS; CYCLOOXYGENASE-2; GASTROINTESTINAL TOXICITY; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; DICLOFENAC POTASSIUM; PRIMARY PREVENTION; EPISODIC MIGRAINE; CLINICAL-TRIAL;

D O I：

10.1007/s40122-023-00501-5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

IntroductionNonsteroidal anti-inflammatory drugs (NSAIDs) have been the first-line choice for the acute treatment of migraine attacks for decades; however, the safety of a particular NSAID is related to its treatment dose, duration, and mechanism of action. Although adverse event (AE) risks differ substantially among individual migraine treatments, increased or prolonged exposure to any NSAID elevates risks and severity of AEs.MethodsFor this narrative review, we conducted a literature search of PubMed until July 2022, focusing on the history, mechanism of action, and treatment guidelines informing the safety and efficacy of celecoxib oral solution for the acute treatment of migraine attacks.ResultsHere we discuss the mechanisms of action of nonselective NSAIDs vs. cyclooxygenase-2 (COX-2) inhibitors, and how these mechanisms underlie the AEs associated with these treatments. We review the clinical trials that influenced the regulatory history of NSAIDs, specifically COX-2 inhibitors, the role of traditional and new formulations of NSAIDs including celecoxib oral solution, and special considerations in the acute treatment of migraine attacks.ConclusionsLow-dose formulations of NSAIDs, such as celecoxib oral solution, provide acute migraine analgesia with similar or fewer associated cardiovascular and gastrointestinal events than previous formulations.

引用

页码：655 / 669

页数：15

共 90 条

[1] The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice [J].

Ailani, Jessica ;

Burch, Rebecca C. ;

Robbins, Matthew S. .

HEADACHE, 2021, 61 (07) :1021-1039

[2]

[Anonymous], 2009, 022165 NDA

[3]

[Anonymous], 2020, ELYXYB CELECOXIB CEL

[4]

[Anonymous], 2010, 022382 NDA

[5]

[Anonymous], 1998, 20998 NDA

[6] Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].

Antman, Elliott M. ;

Bennett, Joel S. ;

Daugherty, Alan ;

Furberg, Curt ;

Roberts, Harold ;

Taubert, Kathryn A. .

CIRCULATION, 2007, 115 (12) :1634-1642

[7] Celecoxib for the prevention of colorectal adenomatous polyps [J].

Arber, Nadir ;

Eagle, Craig J. ;

Spicak, Julius ;

Racz, Istvan ;

Dite, Petr ;

Hajer, Jan ;

Zavoral, Miroslav ;

Lechuga, Maria J. ;

Gerletti, Paola ;

Tang, Jie ;

Rosenstein, Rebecca B. ;

Macdonald, Katie ;

Bhadra, Pritha ;

Fowler, Robert ;

Wittes, Janet ;

Zauber, Ann G. ;

Solomon, Scott D. ;

Levin, Bernard .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :885-895

[8] Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile [J].

Arellano, Felix M. ;

Yood, Marianne Ulcickas ;

Wentworth, Charles E. ;

Oliveria, Susan A. ;

Rivero, Elena ;

Verma, Anila ;

Rothman, Kenneth J. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (12) :861-872

[9] Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data [J].

Bally, Michele ;

Dendukuri, Nandini ;

Rich, Benjamin ;

Nadeau, Lyne ;

Helin-Salmivaara, Arja ;

Garbe, Edeltraut ;

Brophy, James M. .

BMJ-BRITISH MEDICAL JOURNAL, 2017, 357

[10] Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials [J].

Bhala, N. ;

Emberson, J. ;

Merhi, A. ;

Abramson, S. ;

Arber, N. ;

Baron, J. A. ;

Bombardier, C. ;

Cannon, C. ;

Farkouh, M. E. ;

FitzGerald, G. A. ;

Goss, P. ;

Halls, H. ;

Hawk, E. ;

Hawkey, C. ;

Hennekens, C. ;

Hochberg, M. ;

Holland, L. E. ;

Kearney, P. M. ;

Laine, L. ;

Lanas, A. ;

Lance, P. ;

Laupacis, A. ;

Oates, J. ;

Patrono, C. ;

Schnitzer, T. J. ;

Solomon, S. ;

Tugwell, P. ;

Wilson, K. ;

Wittes, J. ;

Baigent, C. ;

Adelowo, O. ;

Aisen, P. ;

Al-Quorain, A. ;

Altman, R. ;

Bakris, G. ;

Baumgartner, H. ;

Bresee, C. ;

Carducci, M. ;

Chang, D-M. ;

Chou, C-T. ;

Clegg, D. ;

Cudkowicz, M. ;

Doody, L. ;

El Miedany, Y. ;

Falandry, C. ;

Farley, J. ;

Ford, L. ;

GarciLosa, M. ;

Gonzalez-Ortiz, M. ;

Haghighi, M. .

LANCET, 2013, 382 (9894) :769-779

← 1 2 3 4 5 6 7 8 9 →